3月20日 - ** 专注于眼部疾病的Eyenovia EYEN.O股价在盘前交易中下跌2.4%，至1.63美元
** Co 表示正在探索 (link) 与私人控股的Betaliq进行反向合并，以合并两家公司专注于眼科疾病的业务
** 拟议交易中，Betaliq的估值约为7700万美元，Eyenovia的估值约为1500万美元
** 如果合并成功，EYEN将持有合并后公司的16.3%股份，Betaliq将持有剩余股份
** EYEN的Optejet设备和Betaliq的EyeSol技术均用于向患者提供FDA批准的眼部护理药物
** 截至上次收盘，EYEN在过去12个月下跌了约2倍
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.